Am J Cardiovasc Drugs. 2021 Mar 22. doi: 10.1007/s40256-021-00474-w. Online ahead of print.
ABSTRACT
The purpose of this current opinion article is to illustrate a novel approach to the treatment of acute decompensated heart failure (ADHF) in coronavirus disease 2019 (COVID-19) patients. The approach described herein relies on a reformulation of intravenous nitroglycerin in 5% glutathione, itself novel, and is felt to have the potential to not only improve the rate of resolution of ADHF, but also reduce the risk of complications of heart failure seen in patients with COVID-19.
PMID:33748918 | DOI:10.1007/s40256-021-00474-w